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pen access Abstract Introduction: Ischemia/reperfusion (I/R) injury and therapy with angiotensin antagonists
were shown to exert signiﬁcant effects on the kidney. The study aimed to investigate the protective
effect, if any, of L-carnitine on the initial nephrotoxic effects of ramipril or losartan on I/R insult in rats.
Methods: I/R was induced through bilateral renal ischemia for 60 min followed by 60 min of reperfu-
sion. Groups I and II received both 1% Tween 80 p.o. and saline i.p. and served as sham-operated and
I/R control groups, respectively. Groups III–VII received 2 weeks pretreatment with ramipril (1 mg/
kg; p.o.), losartan (10 mg/kg; i.p.), L-carnitine (200 mg/kg; i.p.) and L-carnitine plus either ramipril
or losartan, respectively. Chosen markers included kidney function tests, oxidative stress and inﬂam-
matory biomarkers as well as histological assessment of kidney sections.
Results: I/R increased plasma creatinine and urea levels but decreased albumin level; meanwhile, it
increased the kidney tumor necrosis factor-alpha (TNF-a) content, myeloperoxidase (MPO) and
plasma lactate dehydrogenase (LDH) activities. Moreover, I/R decreased kidney carnitine, glutathi-
one, and total nitrate/nitrite contents as well as superoxide dismutase activity. Both ramipril and
losartan elevated creatinine and urea levels; meanwhile, they lowered raised LDH, TNF-a and
MPO as compared to I/R-control group. L-carnitine alone or combined with either agent decreased
creatinine and urea levels, LDH andMPO activities as well as TNF-a content as compared to ramipril
or losartan monotherapy.23639307/23624917, mobile:
com (M.A. Rabie).
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8 M.A. Rabie et al.Conclusions: L-carnitine can protect the kidney from the initial deleterious effects of either ramipril or
losartan in rats subjected to I/R most probably by virtue of its antioxidant and anti-inﬂammatory
effects.
ª 2012 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Acute renal failure (ARF) resulting from ischemia/reperfusion
(I/R) injury is a serious clinical problem. I/R injury in the kid-
ney may occur during transplantation, shock or cardiovascular
surgery.1
The activation of the renin angiotensin system (RAS) plays
critical roles in the progression of chronic kidney disease, such
as diabetic nephropathy.2 Therefore, drugs that inﬂuence the
RAS are used with increasing frequency in the treatment of
chronic renal and vascular diseases. However, a well-known
side effect of such drugs is acute worsening of renal function
in certain patients, depending on the state of hydration and
the kind of pre-existing renal damage, due to predominant
dilatation of efferent arterioles and consequent decrease of
glomerular ﬁltration rate (GFR).3,4
The kidney plays an important role in carnitine homeostasis
due to its ability to reabsorb 95% of carnitine in the glomeru-
lar ﬁltrate. Impairment of this reabsorptive function due to
renal injury can lead to systemic carnitine deﬁciency which
may require supplementation with exogenous carnitine.5
The present study aimed to investigate the protective ef-
fect, if any, of L-carnitine on the initial nephrotoxic effects
of angiotensin antagonists such as ramipril and losartan on
I/R insult in rats. Chosen markers of nephrotoxicity in-
cluded kidney function tests, oxidative stress and inﬂamma-
tory biomarkers as well as histological assessment of
kidney sections.2. Material and methods
2.1. Material
2.1.1. Animals
Adult male albino rats, weighing 200–250 g, were used in the
present study. They were obtained from the animal house of
Faculty of Pharmacy, Cairo University where they were main-
tained under controlled environmental conditions and fed a
standard chow diet (El-Nasr Co., Cairo, Egypt) and water
ad libitum throughout the experimental period. The study
was performed according to the guidelines stated by the ethics
committee of Faculty of Pharmacy, Cairo University.2.1.2. Drugs
L-carnitine was purchased from Sigma–Aldrich (St. Louis,
MO, USA) and losartan was obtained from Unipharma for
Pharmaceutical Industries (Egypt). Both drugs were dissolved
in saline such that each 100 g animal received 0.1 ml of the pre-
pared solution intraperitoneally. Ramipril was obtained from
Pharonia Pharmaceuticals Company (Egypt) and suspended
in 1% Tween 80 such that each 100 g animal received 1 ml
of the prepared suspension orally.2.1.3. Chemicals
Thiobarbituric acid, vanadium III chloride, Ellman’s reagent,
reduced glutathione (GSH), superoxide dismutase (SOD),
1,1-3,3-tetraethoxypropane and hexadecyltrimethyl ammo-
nium bromide were obtained from Sigma–Aldrich (St. Louis,
MO, USA). All other chemicals were of analytical grade.
2.2. Experimental design
Animals were randomly allocated into seven groups each con-
sisting of 10 rats. Drugs were administered daily for 14 succes-
sive days. I/R was performed 1 h after the last dose. Groups I
and II received both 1% Tween 80 p.o. and saline i.p. and
served as sham-operated and I/R control groups, respectively.
Groups III–V received ramipril (1 mg/kg/day; p.o.)6, losartan
(10 mg/kg/day; i.p.)7 and L-carnitine (200 mg/kg/day; i.p.)8,
respectively. Groups VI and VII received L-carnitine with
either ramipril or losartan.
2.3. Methods
2.3.1. Induction of I/R and sampling
On the 14th day, all rats (fasted overnight) were subjected to
ischemia for 60 min followed by 60 min of reperfusion. This
was done in all groups except the 1st one which was just sub-
jected to sham operation.9
At the end of the experiment, blood samples were collected
retro-orbitally in heparinized tubes. The plasma was separated
by centrifugation at 3000 rpm for 15 min at 4 C, then divided
into several aliquots and stored at 20 C until time of analy-
sis. Kidneys were dissected out and used to prepare 10%
homogenate in ice-cold isotonic saline. The prepared homoge-
nate and plasma were used for estimation of the chosen bio-
chemical parameters. Moreover, histological assessment of
kidney sections from all groups was performed.102.3.2. Estimation of renal function tests
Assessment of plasma creatinine, urea and albumin levels was
achieved using commercial kits from Stanbio (USA) and ex-
pressed as mg/dl.2.3.3. Estimation of tissue damage biomarkers
Plasma lactate dehydrogenase (LDH) activity was assessed
using commercial kits from Stanbio (USA) and expressed as
U/L.
2.3.4. Estimation of oxidative stress biomarkers
Kidney content of GSH was determined according to the
method described by Ahmed et al.11 and expressed as lg/g
wet tissue. Kidney SOD activity was determined according
to the method described by Marklund and Marklund12 and
expressed as U/g wet tissue. Kidney total nitrate/nitrite
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Miranda et al.13 and expressed as lmol/g wet tissue.
2.3.5. Estimation of inﬂammatory biomarkers
Tumor necrosis factor-alpha (TNF-a) was determined in the
kidney using a rat TNF-a ELISA kit (Biosource International,
USA) and expressed as pg/g wet tissue. Renal myeloperoxidase
(MPO) activity was assessed according to the method de-
scribed by Manktelow and Meyer14 and expressed as U/g
wet tissue.2.3.6. Renal carnitine content
Carnitine concentration was determined in the kidney homog-
enate according to the method reported by Prieto et al.15 and
expressed as nmol/g wet tissue.2.4. Statistical analysis
Data were presented as means ± SE. A comparison between
different treatment groups was achieved by one way ANOVA
followed by Tukey–Kramer multiple comparison test using
SPSS software version 13. p< 0.05 was chosen as the criterion
for signiﬁcance.3. Results
3.1. Renal function tests
I/R resulted in an increase in plasma levels of creatinine and
urea to about 2- and 3-folds, respectively, as compared to
sham-operated group; meanwhile, it signiﬁcantly decreased
the albumin level to about half its normal value (Table 1).
Pretreatment with either ramipril or losartan signiﬁcantly
increased the creatinine level by 17.24% and 115.56%, respec-
tively; meanwhile, L-carnitine signiﬁcantly decreased creatinine
level by 38.55% as compared to I/R control group. Combina-
tion of L-carnitine with either ramipril or losartan signiﬁcantly
decreased creatinine level by 26.42% and 21.92%, respectively,
as compared to I/R control group and signiﬁcantly decreased
creatinine level as compared to ramipril or losartan mono-
therapy, respectively (Table 1).
Pretreatment with losartan increased urea level by 24.69%;
whereas, pretreatment with L-carnitine signiﬁcantly decreased
urea level by 28.60%, while its combination with losartan
did not signiﬁcantly decrease urea level as compared to I/R
control group, but it signiﬁcantly decreased urea level as com-
pared to losartan monotherapy. On the other hand, pretreat-
ment with ramipril did not signiﬁcantly alter urea level while
its combination with L-carnitine signiﬁcantly decreased urea
level by 18.70% as compared to I/R control group and signif-
icantly decreased urea level as compared to ramipril mono-
therapy (Table 1).
Pretreatment with L-carnitine signiﬁcantly increased the
albumin level by 27.09%; meanwhile, pretreatment with ram-
ipril or losartan did not signiﬁcantly alter the albumin level
as compared to I/R control group. Combination of L-carnitine
with either ramipril or losartan increased the albumin level by
24.13% and 30.52%, respectively, as compared to I/R control
group and signiﬁcantly increased albumin level as compared to
ramipril or losartan monotherapy, respectively (Table 1).3.2. Tissue damage biomarkers
I/R resulted in an increase in the plasma LDH activity to
about 3-folds as compared to sham-operated group. Pretreat-
ment with ramipril or L-carnitine signiﬁcantly decreased plas-
ma LDH activity by 36.12% and 16.67%, respectively;
meanwhile pretreatment with losartan normalized plasma
LDH activity. Combination of L-carnitine with either ramipril
or losartan decreased plasma LDH activity by 42.98% and
22.76%, respectively, as compared to I/R control group and
its combination with ramipril signiﬁcantly decreased plasma
LDH activity as compared to ramipril monotherapy (Fig. 1).
3.3. Oxidative stress biomarkers
I/R showed a signiﬁcant decrease in the kidney GSH content
and SOD activity to 46% and 56% of the normal value,
respectively. Moreover, it resulted in a signiﬁcant decrease in
NOx content to 25% of the normal value (Fig. 2).
Pretreatment with ramipril, L-carnitine or combination of
both agents signiﬁcantly increased GSH content by 80.63%,
47.65% and 156.70%, respectively, as compared to I/R control
group, combination of both agents signiﬁcantly increased
GSH content as compared to ramipril monotherapy, while
pretreatment with losartan or its combination with L-carnitine
normalized GSH content (Fig. 2a).
Pretreatment with ramipril, losartan or L-carnitine signiﬁ-
cantly increased SOD activity by 43.74%, 46.81% and
23.92%, respectively, as compared to I/R control group. Sim-
ilarly, a combination of L-carnitine with either ramipril or
losartan signiﬁcantly increased SOD activity by 53.11% and
67.50%, respectively, as compared to I/R control group
(Fig. 2b).
Pretreatment with ramipril, losartan or L-carnitine signiﬁ-
cantly increased NOx content by 208.95%, 217.52% and
168.34%, respectively, as compared to I/R control group. Sim-
ilarly, a combination of L-carnitine with either ramipril or
losartan signiﬁcantly increased NOx content by 157.28% and
178.90%, respectively, as compared to I/R control group
(Fig. 2c).
3.4. Inﬂammatory biomarkers
I/R showed a signiﬁcant increase in the kidney MPO activity
and TNF-a content to about 3- and 2-folds, respectively, as
compared to sham-operated group (Fig. 3).
Pretreatment with ramipril or losartan normalized the
MPO activity; meanwhile, pretreatment with L-carnitine or
its combination with either ramipril or losartan signiﬁcantly
decreased MPO activity by 32%, 53.90% and 46.71%, respec-
tively, as compared to I/R control group (Fig. 3a).
Pretreatment with either ramipril or losartan or the combi-
nation of L-carnitine with either of the two drugs normalized
TNF-a content; meanwhile, pretreatment with L-carnitine sig-
niﬁcantly decreased TNF-a content by 27.39% as compared to
I/R control group (Fig. 3b).
3.5. Kidney carnitine content
I/R showed a signiﬁcant decrease in the kidney carnitine con-
tent to about 40% of the normal value. Pretreatment with ram-
ipril normalized the kidney carnitine content. Pretreatment
Table 1 Effect of two weeks daily pre-treatment with ramipril, losartan and L-carnitine alone or in combination on plasma levels of
creatinine, urea and albumin in rats subjected to renal ischemia/reperfusion (I/R).
Treatments Parameters
Creatinine (mg/dl) Urea (mg/dl) Albumin (mg/dl)
Sham-operated control (1% Tween 80; p.o. + saline i.p.) 0.65 ± 0.02 22.42 ± 0.80 3.09 ± 0.03
I/R control (1% Tween 80; p.o. + saline i.p.) 1.35 ± 0.04* 67.17 ± 1.94* 1.54 ± 0.05*
Ramipril (1 mg/kg/day; p.o.) 1.58 ± 0.03*,@ 63.41 ± 6.28* 1.80 ± 0.07*
Losartan (10 mg/kg/day; i.p.) 2.91 ± 0.09*,@ 83.75 ± 4.44*,@ 1.70 ± 0.09*
L-carnitine (200 mg/kg/day; i.p.) 0.83 ± 0.03*,@ 47.96 ± 2.59*,@ 1.96 ± 0.11*,@
Ramipril + L-carnitine 0.99 ± 0.03*,@,# 54.61 ± 3.56*,@,# 1.91 ± 0.08*,@,#
Losartan + L-carnitine 1.05 ± 0.04*,@,/ 65.69 ± 7.28*,/ 2.01 ± 0.15*,@,/
Animals were pre-treated daily for 14 successive days with the test agents and subjected to I/R on the 14th day.
Each value represents mean of 8–10 rats ± SE.
Statistical analysis was performed using one way ANOVA followed by Tukey–Kramer multiple comparisons test.
* Signiﬁcantly different from sham-operated control group at p< 0.05.
@ Signiﬁcantly different from I/R control group at p< 0.05.
# Signiﬁcantly different from ramipril group at p< 0.05.
/ Signiﬁcantly different from losartan group at p< 0.05.
Figure 1 Effect of two weeks daily pre-treatment with ramipril, losartan and L-carnitine alone or in combination on plasma lactate
dehydrogenase (LDH) activity in rats subjected to renal ischemia/reperfusion (I/R). Each bar with vertical line represents mean of 8–10
rats ± SE. Statistical analysis was performed using one way ANOVA followed by Tukey–Kramer multiple comparisons test.
*Signiﬁcantly different from sham-operated control group at p< 0.05. @Signiﬁcantly different from I/R control group at p< 0.05.
#Signiﬁcantly different from ramipril group at p< 0.05. uSigniﬁcantly different from losartan group at p< 0.05.
10 M.A. Rabie et al.with losartan, L-carnitine and the combination of L-carnitine
with either ramipril or losartan signiﬁcantly increased the kid-
ney carnitine content by 244.67%, 262.03%, 288.98% and
325.51%, respectively, as compared to I/R control group.
Combination of L-carnitine with either ramipril or losartan sig-
niﬁcantly increased the kidney carnitine content as compared
to ramipril or losartan monotherapy, respectively (Fig. 4).
3.6. Histopathological examination of kidney sections
A section of a kidney of a sham-operated rat shows the normal
architecture of renal tissue, being composed of a number of
glomeruli embedded among a great number of different tu-
bules which are the proximal and the distal convoluted tubules
(Fig. 5a).
Induction of I/R resulted in a marked vacuolar degenera-
tion in the lining epithelium of the tubules, interstitial edema
and hemorrhage with cellular debris in the lumen of the tu-
bules (Fig. 5b and c).
In the groups pretreated with ramipril or losartan before
I/R, most of the tubules appeared normal in shape, exceptfor a few ones that showed vacuolar degeneration in their lin-
ing epithelium and dilated blood capillaries (Fig. 6a and b).
Pretreatment with L-carnitine prevented I/R-induced degen-
eration in the tubular epithelium (Fig. 6c and d). Similarly, the
combination of L-carnitine with either ramipril or losartan
ameliorated most of the changes caused by either of the two
drugs alone (Fig. 7a and b).
4. Discussion
In the present study, I/R resulted in marked glomerular and
tubular dysfunction as evidenced by elevation of plasma creat-
inine and urea levels as well as reduction in albumin level.
These results further support that reported previously by Sener
et al.16 Histopathological examination of I/R kidney sections
showed marked vacuolar degeneration in the lining epithelium
of the tubules, interstitial edema and hemorrhage with cellular
debris in the lumen of the tubules.
The present elevation of LDH activity is considered as a
marker of extensive necrosis consequent to I/R-induced oxida-
tive stress leading to leakage of cellular contents as LDH.17
Figure 2 Effect of two weeks daily pre-treatment with ramipril, losartan and L-carnitine alone or in combination on kidney (a)
glutathione (GSH) content, (b) superoxide dismutase (SOD) activity as well as (c) total nitrate/nitrite (NOx) content in rats subjected to
renal ischemia/reperfusion (I/R). Each bar with vertical line represents mean of 8–10 rats ± SE. Statistical analysis was performed using
one way ANOVA followed by Tukey–Kramer multiple comparisons test. *Signiﬁcantly different from sham-operated control group at
p< 0.05. @Signiﬁcantly different from I/R control group at p< 0.05. #Signiﬁcantly different from ramipril group at p< 0.05.
uSigniﬁcantly different from losartan group at p< 0.05.
Angiotensin antagonists and renal ischemia/reperfusion: Possible modulation by L-carnitine 11The observed reduction in GSH content is probably due to
its consumption during oxidative stress known to be associated
by I/R.18 A signiﬁcant decrease in SOD activity was also ob-
served which is in accordance to that reported by Feng
et al.19 Hypoxia, resulting from ischemia and subsequent
reperfusion, is characterized by increased production of reac-
tive oxidative species (ROS) and decreased efﬁcacy of the anti-
oxidant defenses as SOD.20
The observed interstitial edema, in histopathological sec-
tions, caused by I/R in the present study was supported by
the elevation of inﬂammatory biomarkers such as renal
TNF-a content and MPO activity. Similar results were previ-
ously reported.18,21 Renal TNF-a contributes to neutrophil
inﬁltration and early injury after I/R.22
Polymorphonuclear leukocytes accumulated during reper-
fusion have long been implicated as critical mediators of I/R
injury. These cells are a potential source of ROS and have a
major role in the development of oxidative tissue injury.23 Sim-
ilarly, the present increase in MPO activity in the kidney tissue
following I/R is expected as MPO is primarily found in neutro-
phils and its activity reﬂects neutrophil inﬁltration in tissues.24
The observed decrease in NOx content due to I/R injury is
in accordance with that reported by Lieberthal et al.25 whoshowed an impaired endothelium-dependent vascular relaxa-
tion in I/R. It is suggested that a reduced production of nitric
oxide (NO) through impairment in its synthetic pathway is in-
volved in renal failure.26 NO plays a key role not only in the
regulation of renal hemodynamics but also in renal tubular
function.27
I/R-induced renal dysfunction could be also related to en-
ergy starvation as shown by a low carnitine content in I/R
group. Similar results were obtained by Aleisa et al.28 who re-
ported that cisplatin-induced carnitine deﬁciency and ATP
depletion could lead to renal dysfunction. I/R was proven to
cause severe damage to renal proximal tubules29 leading to im-
paired renal synthesis and inhibition of tubular reabsorption of
carnitine.30
The present study showed that both ramipril and losartan
administration augmented glomerular dysfunction induced
by I/R on the kidney, where signiﬁcant elevation in plasma cre-
atinine and urea levels was observed. These results were further
conﬁrmed by the histopathological examination of kidney sec-
tions from these groups. Retention of creatinine and urea dur-
ing therapy with angiotensin antagonists was reported by
Demeilliers et al.31 in one kidney, one clip Na+ restricted rats
and Helmchen et al.32 in hypertensive rats with bilaterally
Figure 3 Effect of two weeks daily pre-treatment with ramipril, losartan and L-carnitine alone or in combination on kidney (a)
myeloperoxidase (MPO) activity and (b) tumor necrosis factor-alpha (TNF-a) content in rats subjected to renal ischemia/reperfusion (I/
R). Each bar with vertical line represents mean of 8–10 rats ± SE. Statistical analysis was performed using one way ANOVA followed by
Tukey–Kramer multiple comparisons test. *Signiﬁcantly different from sham-operated control group at p< 0.05. @Signiﬁcantly different
from I/R control group at p< 0.05.
Figure 4 Effect of two weeks daily pre-treatment with ramipril, losartan and L-carnitine alone or in combination on kidney carnitine
content in rats subjected to renal ischemia/reperfusion (I/R). Each bar with vertical line represents mean of 8–10 rats ± SE. Statistical
analysis was performed using one way ANOVA followed by Tukey–Kramer multiple comparisons test. *Signiﬁcantly different from sham-
operated control group at p< 0.05. @Signiﬁcantly different from I/R control group at p< 0.05. #Signiﬁcantly different from ramipril
group at p< 0.05. uSigniﬁcantly different from losartan group at p< 0.05.
12 M.A. Rabie et al.constricted renal arteries. ARF complicating Ang II antago-
nists’ therapy is almost caused by the loss of GFR resulting
from an inadequate glomerular capillary pressure.33
Ang II has been considered to be involved through an Ang
II type 1 receptor-NADPH oxidase pathway in the production
of ROS by the mesangial and tubular cells,34 hence preventing
such actions by ACE inhibition or Ang II receptor blockade
could explain the present decrease in oxidative stress biomark-
ers by ramipril and losartan pretreatment. This could also ex-
plain the observed reduction in LDH activity which reﬂects
tissue injury consequent to oxidative stress.
In the current study, administration of ramipril or losar-
tan normalized I/R-induced increase in MPO activity and
TNF-a content. This was coupled by reduction in renal
interstitial inﬂammation shown in the histopathologicalexamination. The present data are in accordance with previ-
ous reports which demonstrated that ACE-inhibition pre-
vents postischemic coronary leukocyte adhesion and
leukocyte-dependent reperfusion injury.35 Kra´mer et al.36
also reported anti-inﬂammatory and antiaggregatory proper-
ties of losartan.
Pretreatment with ramipril or losartan in the present study
was shown to increase the kidney NOx content. Mechanisms
that account for the effects of ACE inhibitors and ARBs on
vascular dysfunction have been reported to be related to
potentiating the actions of bradykinin in spontaneously hyper-
tensive rats,37 an increase in nitric oxide synthase (NOS) activ-
ity in aging rats,38 and/or by inhibiting the inﬂuence of Ang II
on oxidative stress39 which subsequently leads to improving
the biological half-life of NO.40
Figure 5 Sections of kidneys from (a) normal rat showing the normal architecture of renal tissue, being composed of a number of
glomeruli (G) embedded among a great number of different tubules. The most prominent of these tubules were the proximal convoluted
tubules (arrow head) lined with pyramidal cells and the distal convoluted tubules (arrow) with larger diameter and lined with cuboidal
cells; (b and c) rats subjected to ischemia/reperfusion showing marked vacuolar degeneration in the lining epithelium of the tubules (arrow
head) as well as interstitial edema and hemorrhage (arrow) with cellular debris in the lumen of the tubules (H and E · 200).
Figure 6 Sections of kidneys of rats subjected to ischemia/reperfusion-induced nephrotoxicity after treatment with (a) ramipril showing
glomeruli with signs of vacuolar degeneration (arrow head) with most of the tubules appearing normal in shape (arrow), except for a few
ones that show signs of vacuolar degeneration (arrow) in their lining epithelium. Blood capillaries (wavy arrow) appear more or less
dilated denoting increased blood ﬂow; (b) losartan showing dilated blood capillaries (arrow) and small areas of hemorrhage in between the
tubules (arrow head) and (c and d) L-carnitine showing no signs of degeneration in the tubular epithelium, but cellular debris were still
present in the lumen of the tubules (arrow) denoting a process of regeneration and increased urinary space in the renal corpuscle and in the
interstitial tissue (arrow head) denoting increased urinary output (H and E · 200).
Angiotensin antagonists and renal ischemia/reperfusion: Possible modulation by L-carnitine 13In the present study, pretreatment with L-carnitine im-
proved I/R-induced kidney dysfunction as it decreased plasma
creatinine and urea levels and increased albumin level. Histop-
athologically, sections from L-carnitine-treated group showed
no signs of degeneration in the tubular epithelium. PropylL-carnitine, an ester derivative of L-carnitine, has been found
to be of value in preventing decline in renal function that oc-
curs during I/R.41
Moreover, Ahmad et al.42 reported that carnitine adminis-
tration to patients undergoing hemodialysis in end-stage renal
Figure 7 Sections of kidneys of rats subjected to ischemia/reperfusion-induced nephrotoxicity after treatment with (a) ramipril + L-
carnitine showing little degeneration in some of the tubules and slight edema denoting reduction of the interstitial inﬂammation and (b)
losartan + L-carnitine showing most of the tubules normal in shape, only some of them show degrees of vacuolar degeneration with little
interstitial hemorrhage. (H and E · 100).
14 M.A. Rabie et al.disease decreased protein catabolism and/or enhanced protein
synthesis, thereby reducing serum concentrations of the prod-
ucts of protein catabolism, including urea, creatinine and
phosphorus.
Pretreatment with L-carnitine signiﬁcantly increased GSH
content and SOD activity and decreased LDH activity. Chang
et al.43 reported that L-carnitine suppressed the release of free
electrons from mitochondrial electron transport systems, a
prerequisite reaction to the generation of ROS.
L-carnitine pretreatment completely reversed the I/R-in-
duced decrease in carnitine content to control values. L-carni-
tine accumulates in the kidney and stimulates shuttling of
long-chain fatty acids across the inner mitochondrial mem-
brane for beta-oxidation in mitochondria, with a consequent
increase in ATP production which could account for some of
the favorable effects caused by L-carnitine.44
Pretreatment with L-carnitine in the present study also de-
creased kidney TNF-a content, MPO activity and increased
NOx content.
The study by Gorur et al.45 reported that L-carnitine was
associated with a decreased tissue inﬂammation and neutrophil
inﬁltration in a rat kidney I/R injury model, which supports
the ﬁndings of the present study.
Carnitine interacts with NO/cGMP system at least in part
through its ability to increase both endothelial NOS gene
and protein expressions. As a result, it is expected to provide
protection from oxidative stress through increased bioavail-
ability of NO which has also been shown to have antioxidant
effects.46
The current study showed that the combined administra-
tion of L-carnitine with either ramipril or losartan decreased
plasma levels of creatinine and urea and increased albumin
level. Thus both agents could serve to reduce the deleterious
effects of ACE inhibitors and ARBs in this perspective.
In the present investigation, combined administration of
L-carnitine with either ramipril or losartan caused enhancement
of renal GSH content as well as reduction of plasma LDH
activity. The improvement produced by the latter combinations
can be attributed to the previously discussed antioxidant activ-
ities reported for each of the used agents.34,43
Data of the present work revealed that pretreatment of rats
with ramipril or losartan in combination with L-carnitine
decreased inﬂammatory biomarkers and MPO activity owing
to their documented anti-inﬂammatory properties.35,36,45On the other hand, the apparent antagonism of losartan ef-
fects on plasma LDH activity when combined with L-carnitine
may need further studies to investigate underlying mechanisms.5. Conclusions
I/R exerted deleterious effects on kidney functions via enhanc-
ing the production of oxidative stress and inﬂammatory bio-
markers as well as interference with energy stores. Both
ramipril and losartan caused signiﬁcant worsening in kidney
function tests as evidenced by elevated creatinine and urea lev-
els; meanwhile, they ameliorated oxidative stress and inﬂam-
matory biomarkers. L-carnitine protected against I/R-induced
changes. Moreover, its combination with either ramipril or
losartan attenuated some of their harmful effects on GFR.
The favorable effects of L-carnitine are probably mediated by
virtue of its antioxidant and anti-inﬂammatory effects or by
a mechanism related to its ability to increase the intracellular
carnitine content, with a consequent improvement in mito-
chondrial oxidative phosphorylation and energy production.
This will open new perspectives for the use of L-carnitine in
the treatment of renal diseases associated with or secondary
to carnitine deﬁciency as acute renal insufﬁciency.Acknowledgement
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